Emerging drugs for adult acute lymphoblastic leukaemia

Expert Opinion on Emerging Drugs

Volumn 10, Issue 3, 2005, Pages 591-617

  Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukaemia; Chemotherapy; Emerging drugs; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; BORTEZOMIB; CLOFARABINE; CYTARABINE; DASATINIB; DAUNORUBICIN; DOXORUBICIN; EVEROLIMUS; FLUDARABINE PHOSPHATE; IMATINIB; IMMUCILLIN H; LY 450139; MERCAPTOPURINE; NELARABINE; NILOTINIB; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS; TIPIFARNIB; TRIPTOLIDE; TRIPTOLIDE SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; EDEMA; ENZYME ACTIVITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PROGNOSIS; REMISSION; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT PLANNING; VERTIGO; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2;

EID: 23844531209     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.3.591     Document Type: Review

References (162)

1. BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the acute leukemias. Br. J. Haematol. (1976) 33:451-458. Provides the criteria for morphological diagnosis of ALL.
2. RAIMONDI SC, BEHM FG, ROBERSON PK et al.: Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J. Clin. Oncol. (1990) 8:1380-1388.
3. BERNARD A, BOUMSELL L, REINHERZ E et al.: Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood (1981) 57:1105-1110.
4. BENE MC, CASTOLDI C, KNAPP W et al.: Proposals for the immunological classification of acute leukemias. Leukemia (1995) 9:1783-1786. Provides the criteria for immunological classification of ALL.
5. PRETI HA, HUH YO, O'BRIEN SM et al.: Myeloid markers in adult acute lymphoblastic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer (1995) 76:1564-1570.
6. DREXLER HG, LUDWIG WD: Incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Recent Results Cancer Res. (1993) 131:53-66.
7. HOUOT R, TAVERNIER E, LE QH et al.: Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology (2004) 9:369-376.
8. MANCINI M, SCAPPATICCI D, CIMINO G et al.: A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood (2005) 105:3434-3441.
9. WETZLER M, DODGE RK, MRUZEK K et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood (1999) 93:3983-3993.
10. PUI CH: Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr. Opin. Hematol. (1998) 5:292-301. A comprehensive review of childhood ALL.
11. HOELZER D: Therapy of the newly-diagnosed adults with acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. (1993) 7:139-160.
12. LARSON RA, DODGE RK, BURNS CP et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood (1995) 85:2025-2037.
13. KANTARJIAN H, O'BRIEN S, SMITH TL et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. (2000) 18:547-561. A pivotal study in the treatment of adult ALL.
14. THOMAS X, BOIRON JM, HUGUET F et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J. Clin. Oncol. (2004) 22:4075-4086. A risk-adapted postremission strategy trial.
15. ROWE JM, RICHARDS S, BURNETT AK et al.: Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the International ALL trial (MRC UKALL XII/ECOG E2993). Blood (2001) 98:481a. An important study in adult ALL based on risk-adapted strategy.
16. GOEKBUGET N, ARNOLD R, BUECHNER T et al.: Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93. Blood (2001) 98(Suppl. 1):802a.
17. LINKER C, DAMON L, RIES C et al.: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J. Clin. Oncol. (2002) 20:2464-2471.
18. ANNINO L, VEGNA ML, CAMERA A et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 99:863-871.
19. ANNINO L, GOEKBUGET N, DELANNOY A: Acute lymphoblastic leukemia in the elderly. Hematol. J. (2002) 3:219-223. A review of ALL in the elderly.
20. TAKEUCHI J, KYO T, NAITO K et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia (2002) 16:1259-1266.
21. HOELZER D, LUDWIG WD, THIEL E et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 87:495-508.
22. THOMAS D, CORTES J, O'BRIEN S et al.: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J. Clin. Oncol. (1999) 17:2461-2470.
23. ASNAFIV, BUZYN A, THOMAS X et al.: Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood (2005) 105:3072-3078.
24. KRAMPERA M, VITALE A, VINCENZI C et al.: Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br. J. Haematol. (2003) 120:74-79.
25. KANTARJIAN H, THOMAS D, O'BRIEN S et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer (2004) 101:2788-2801.
26. BLUM KA, LOZANSKI G, BYRD JC: Adult Burkitt leukemia and lymphoma. Blood (2004) 104:3009-3020. A comprehensive review of mature B-cell ALL in adults.
27. FADERL S, KANTARJIAN HM, THOMAS DA et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk. Lymphoma (2000) 36:263-273.
28. DOMBRET H, GABERT J, BOIRON JM et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood (2002) 100:2357-2366.
29. EVANS WE, RELLING MV, RODMAN JH et al.: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. (1998) 338:499-505.
30. HOLLEMAN A, CHEOK MH, DEN BOER ML et al.: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. (2004) 351:533-542. A very impressive study that contains data on gene expression patterns according to sensitivity or resistance to the four major drugs used in ALL treatment.
31. HOELZER D, THIEL E, LOFFLER H et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 71:123-131. A pivotal study regarding prognostic factors in adult ALL.
32. KANTARJIAN HM, WALTERS RS, KEATING MJ et al.: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J. Clin. Oncol. (1990) 8:994-1004.
33. GAYNOR J, CHAPMAN D, LITTLE C et al.: A cause-specific hazard rate analysis of prognostic factor among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J. Clin. Oncol. (1988) 6:1014-1030. A pivotal study proposing a prognostic model.
34. GOASGUEN JE, DOSSOT JM, FARDEL O et al.: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood (1993) 81:2394-2398.
35. HESS CE, ZIRKLE JW: Results of induction therapy with vincristine and prednisone alone in adult acute lymphoblastic leukemia: report of 43 patients and review of the literature. Am. J. Hematol. (1982) 13:63-71.
36. GOTTLIEB AJ, WEINBERG V, ELLISON RR et al.: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomised trial by the Cancer and Leukemia Group B. Blood (1984) 64:267-274.
37. BASSAN R, ROHATINER AZ, LEREDE T et al.: Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Hematol. J. (2000) 1:226-234.
38. BALIS FM, LESTER CM, CHROUSOS GP et al.: Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J. Clin. Oncol. (1987) 5:202-207.
39. BASSAN R, POGLIANI E, LEREDE T et al.: Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a Phase II clinical study. Haematologica (1999) 84:1088-1093.
40. WEISS M, MASLAK P, FELDMAN E et al.: Cytarabine with high dose mitoxantrone induces rapid complete remissions in adult acute lymhoblastic leukemia (ALL) without the use of vincristine or prednisone. J. Clin. Oncol. (1996) 14:2480-2485.
41. TODESCHINI G, TECCHIO C, MENEGHINI V et al.: Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive Phase II protocol based on high induction dose of daunorubicin. Leukemia (1998) 12:144-149. An important study highlighting the pivotal role of anthracycline administration in ALL treatment.
42. CORTES J, O'BRIEN S, ESTEY E et al.: Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest. New Drugs (1999) 17:81-87.
43. LARSON RA, DODGE RK, LINKER CA et al.: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood (1998) 92:1556-1564. A randomised controlled study.
44. THOMAS X, BOIRON JM, HUGUET F et al.: Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol. J. (2004) 5:384-394.
45. CORTES J, O'BRIEN S, PIERCE S et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood (1995) 86:2091-2097.
46. CASSILETH PA, ANDERSEN JW, BENNETT JM et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia (1992) 62:178-181.
47. MILLER DR, LEIKIN SL, ALBO VC et al.: Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J. Clin. Oncol. (1989) 7:316-325.
48. MANDELLI F, ANNINO L, ROTOLI B: The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br. J. Haematol. (1996) 92:665-672.
49. OMURA GA, MOFFITT A, VOGLERWR et al.: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood (1980) 55:199-204.
50. KANTARJIAN HM, WALTERS RS, SMITH TL et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood (1988) 72:1784-1789.
51. CHAO N, FORMEN S, SCHMIDT G et al.: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood (1991) 78:1923-1927.
52. LABAR B, SUCIU S, ZITTOUN R et al.: Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients < or = 50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica (2004) 89:809-817.
53. HUNAULT M, HAROUSSEAU JL, DELAIN M et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood (2004) 104:3028-3037.
54. GUPTA V, YI QL, BRANDWEIN J et al.: The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor versus no donor comparison. Bone Marrow Transplant (2004) 33:397-404.
55. THIEBAUT A, VERNANT JP, DEGOS L et al.: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol. Oncol. Clin. North Am. (2000) 14:1353-1366.
56. KIEHL MG, KRAUT L, SCHWERDTFEGER R et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J. Clin. Oncol. (2004) 22:2816-2825.
57. POWLES R, SIROHI B, TRELEAVEN J et al.: The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood (2002) 100:1641-1647.
58. GARCIA-MANERO G, THOMAS DA: Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol. Oncol. Clin. North Am. (2001) 15:163-205.
59. EGERER G, GOLDSCHMIDT H, ZOZ M et al.: Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia. Leuk. Lymphoma (2003) 44:9-14.
60. SINGHAL S, HENSLEE-DOWNEY PJ, POWLES R et al.: Haploidentical versus autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplant (2003) 31:889-895.
61. WEISDORF D, BISHOP M, DHARAN B et al.: Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol. Blood Marrow Transplant (2002) 8:213-220.
62. DAVIES SM, RAMSAY NK, WEISDORF DJ: Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant. (1996) 17:737-740.
63. GOEKBUGET N, HOELZER D: Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann. Hematol. (2004) 83:201-205. A comprehensive review of treatment with mAbs in acute leukaemia.
64. THOMAS DA, CORTES J, GILES FJ et al.: Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood (2002) 100(Suppl. 1):763a-764a.
65. MCMAHON S, WOOD M, COLE M: The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-myc. Mol. Cell Biol. (2000) 20:556-562.
66. SMITH J, WICKSTROM E: Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorogenesis in a murine B-cell lymphoma transplant model. J. Natl. Cancer Inst. (1998) 90:1146-1154.
67. ORLOWSKI R, ESWARA J, ORLOWSKI M et al.: Novel demonstration of tumor growth delay in a murine model of human Burkitt's lymphoma after treatment with a proteosome inhibitor. Proc. Am. Soc. Clin. Oncol. (1998): 1717.
68. SERAFEIM A, HOLDER M, GRAFTON G et al.: Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood (2003) 101:3212-3219.
69. FARRELL C, LEE J, SHIN E et al.: Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl. Acad. Sci. USA (2004) 101:4625-4630.
70. CAMPESE AF, BELLAVIA D, GULINO A et al.: Notch signalling at the crossroads of T cell development and leukemogenesis. Semin. Cell. Dev. Biol. (2003) 14:151-157.
71. GRIDLEY T: Kick it up a Notch: NOTCH 1 activation in T-ALL. Cancer Cell (2004) 6:431-432.
72. WENG AP, FERRANDO AA, LEE W et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306:269-271. A comprehensible review.
73. BARBER KE, MARTINEAU M, HAREWOOD L et al.: Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia (2004) 18:1153-1156.
74. GRAUX C, COOLS J, MELOTTE C et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat. Genet. (2004) 36:1084-1089. Explains a useful concept.
75. BANTIA S, KILPATRICK JM: Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr. Opin. Drug Discov. Devel. (2004) 7:243-247. A comprehensive review of PNP inhibitors.
76. SCHMELZLE T, HALL MN: TOR, a central controller of cell growth. Cell (2000) 103:253-262.
77. BROWN VI, FANG J, ALCORN K et al.: Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. PNAS (2003) 100:15113-15118.
78. STERNBERG DW, LIGHT JD: Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr. Opin. Hematol. (2005) 12:7-13. A comprehensive review of FLT3 and its potential inhibitors in acute leukaemias.
79. ARMSTRONG SA, MABON ME, SILVERMAN LB et al.: FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2004) 103:3544-3546.
80. TAKETANI T, TAKI T, SUGITA K et al.: FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood (2004) 103:1085-1088.
81. PAIETTA E, FERRANDO AA, NEUBERG D et al.: Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood (2004) 104:558-560.
82. BROWN P, LEVIS M, SHURTLEFF S et al.: FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2005) 105:812-820. An interesting study of FLT3 inhibition action on ALL cells.
83. KORDES U, KRAPPMANN D, HEISSMEYER V et al.: Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia (2000) 14:399-402.
84. MORI N, FUJII M, IKEDA S et al.: Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood (1999) 93:2360-2368.
85. KHARAS MG, FRUMAN DA: ABL oncogenes and phosphoinoside 3-kinase: mechanism of activation and downstream effectors. Cancer Res. (2005) 65:2047-2053.
86. BRUNNER TB, HAHN SM, GUPTA AK et al.: Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. (2003) 63:5656-5668. A comprehensive review of farnesyltransferase inhibitors.
87. MUGGIA FM: Liposomal encapsuled anthracyclines: new therapeutic horizons. Curr. Oncol. Rep. (2001) 3:156-162.
88. ALLEN TM, MARTIN FJ: Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. (2003) 31:5-15.
89. THOMAS DA, SARRIS A, O'BRIEN S et al.: Phase II study of liposomal vincristine in relapsed or refractory adult acute lymphoblastic leukemia. Blood (1999) 94(Suppl. 1):238b.
90. MURRY DJ, BLANEY SM: Clinical pharmacology of encapsuled sustained-release cytarabine. Ann. Pharmacother. (2000) 34:1173-1178.
91. BOMGAARS J, GEYER J, FRANKLIN J et al.: A Phase I study of intrathecal liposomal cytarabine (DepoCyt) in pediatric patients with advanced meningeal malignancies. Proc. Am. Soc. Clin. Oncol. (2002) 20:433.
92. GLANTZ MJ, JAECKLE KA, CHAMBERLAIN MC et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. (1999) 5:3394-3402.
93. GRAHAM ML: Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. (2003) 55:1293-1302.
94. AVRAMIS VI, SENCER S, PERICLOU AP et al.: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of hildren with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood (2002) 99:1986-1994.
95. AGUAYO A, CORTES J, THOMAS D et al.: Combination therapy with methotrexate, vincristine, polyethyleneglycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer (1999) 86:1203-1209.
96. JEHA S, GANDHI V, CHAN KW et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103:784-789.
97. RIVARD GE, MOMPARLER RL, DEMERS J et al.: Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res. (1981) 5:453-462.
98. MOMPARLER RL, RIVARD GE, GYGER M: Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol. Ther. (1985) 30:277-286.
99. ISSA JPJ, GARCIA-MANERO G, GILES FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 103:1635-1640.
100. WARRELL RP JR, BERMAN E: Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. (1986) 4:74-79.
101. GANDHI V, KEMENA A, KEATING MJ et al.: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. (1992) 52:897-903.
102. CLAVIO M, VENTURING C, PIERRI I et al.: Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann. Hematol. (2004) 83:696-703.
103. KURTZBERG J, ERNST TJ, KEATING MJ et al.: A Phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a censecutive five day schedule in children and adults with refractory hematologic malignancies. Blood (1999) 94(Suppl. 1):629a.
104. CZUCZMAN MS, PORCU P, JOHNSON J et al.: CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL. Blood (2004) 104(Suppl. 1):682a.
105. GANDHI V, PLUNKETT W, WELLER S et al.: Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J. Clin. Oncol. (2001) 19:2142-2152.
106. NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structure of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236-4243.
107. BERAN M, CAO X, ESTROV Z et al.: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M, 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. (1998) 4:1661-1672.
108. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast phase of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042. The first clinical study using imatinib mesylate in ALL.
109. TALPAZ M, SAWYERS CL, KANTARJIAN H et al.: Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blastic crisis. Proc. Am. Soc. Clin. Oncol. (2000) 19:4a.
110. OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100:1965-1971.
111. + ALL) relapsing after allogeneic stem cell transplantation (allo-SCT). Blood (2001) 98(Suppl. 1):589a. A pivotal study on efficacy of STI-571 in Ph-positive ALL.
112. THOMAS DA, FADERL S, CORTES J et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2004) 103:4396-4407.
113. YANADA M, EMI N, USUI N et al.: Combination of intensive chemotherapy and imatinib (IDEAMOP regimen) for the treatment of newly diagnosed BCR-ABL positive acute lymphoblastic leukemia: excellent efficacy without increasing toxicity. Blood (2004) 104(Suppl. 1):748a.
114. DOMBRET H, WITZ F, DE BOTTON S et al.: Imatinib combined with intensive HAM chemotherapy as consolidation of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). Preliminary results of the AFR03 Phase I/II study. Blood (2004) 104(Suppl. 1):749a.
115. LEE S, KIM YJ, MIN CK et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2005) 105:3449-3457.
116. VIGNETTI M, FAZI P, MELONI G et al.: Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201. Blood (2004) 104(Suppl. 1):749a.
117. + ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy. An interim analysis of the GRAALL AFR09 trial. Blood (2004) 104(Suppl. 1):750a.
118. DAUB H, SPECHT K, ULLRICH A: Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. (2004) 3:1001-1010. A comprehensive review of resistance to imatinib mesylate.
119. LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6- methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47:6658-6661.
120. SHAH NP, TRAN C, LEE FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
121. GOLEMOVIC M, BERAN M, GILES F et al.: AMN107, novel aminopyrimidine inhibitor of Bcr-Abl, is significantly more potent than imatinib mesylate against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Blood (2004) 104(Suppl. 1):547a.
122. SAWYERS CL, SHAH NP, KANTERJIAN HM et al.: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a Phase I dose escalation study. Blood (2004) 104(Suppl. 1):4a. The first application of BMS-354825 therapy to BCR-ABL leukaemia.
123. WEISBERG E, MANLEY PW, BREITENSTEIN W et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. (2005) 7:129-141.
124. +) acute lymphocytic leukemia (ALL). Blood (2004) 104(Suppl. 1):10a-11a. An interesting study highlighting the potential efficacy of AMN 107 in Ph-positive ALL.
125. PROPPER DJ, MCDONALD AC, MAN A et al.: Phase I and pharmakokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. (2001) 19:1485-1492.
126. ARMSTRONG SA, KUNG AL, MABON ME et al.: Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3:173-183.
127. IWATA H, WADA Y, WALSH M et al.: In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor. Transplant Proc. (1998) 30:983-986.
128. MORRIS PE, OMURA G: Inhibitors of the enzyme purine nucleoside phosphorylation as potential therapy for psoriasis. Curr. Pharm. Des. (2000) 6:943-959.
129. VIEGAS TX, OMURA GA, STOLTZ RR et al.: Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. (2000) 40:410-420.
130. KILPATRICK JM, HARMAN L, PHILIPS D et al.: Intravenous and oral pharmacokinetic and pharmacodynamic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. FASEB J. (2004) 18:4-5.
131. THOMAS DA, WIERDA W, FADERL S et al.: Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies. Blood (2003) 102(Suppl. 1):261b-262b.
132. ISOLA L, FURMAN RR, GANDHI V et al.: Antileukemic activity and pharmacodynamics of intravenous Forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in Phase I/II trials in patients with advanced T-cell malignancies. Blood (2004) 104(Suppl. 1):208b-209b.
133. FURMAN RR, GANDHI W, BENNETT JC et al.: Intravenous Forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in Phase I/II studies in patients with B-Cell acute lymphoblastic leukemia. Blood (2004) 104(Suppl. 1):750a.
134. VIGNOT S, FAIVRE S, AGUIRRE D et al.: mTOR-targeted therapy of cancer with rapamacyn derivatives. Ann. Oncol. (2005) 16:525-537.
135. YEE KWL, GARCIA-MANERO G, THOMAS D et al.: Phase II study of temsirolimus (CCI-779) in patients with advanced leukemias. Blood (2004) 104(Suppl. 1):214b.
136. BROWN VI, BARR R, ALCORN K et al.: The mTOR inhibitor RAD001 demonstrates activity in preclinical models of acute lymphoblastic leukemia (ALL). Proc. Am. Assoc. Cancer Res. (2003) 44:1593a.
137. YEE KWL, WIERDA W, O'BRIEN S et al.: A Phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies. Blood (2004) 104(Suppl. 1):287b.
138. METCALF C, BOHACEK R, ROZAMUS L et al.: Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc. Am. Assoc. Cancer Res. (2004) 45:2476a.
139. RIVERA V, TANG H, METCALF C et al.: Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc. Am. Assoc. Cancer Res. (2004) 45:3887a.
140. DESAI AA, JANISCH L, BERK LR et al.: A Phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc. Am. Soc. Clin. Oncol. (2004) 23:232.
141. KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361-3369.
142. HOOVER RR, MAHON FX, MELO JV et al.: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 100:1068-1071.
143. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59:2615-2622.
144. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteosome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20:4420-4427.
145. CORTES J, THOMAS D, KOLLER C et al.: Phase I of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. (2004) 10:3371-3376.
146. CHANG WT, KANG JJ, LEE KY et al.: Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J. Biol. Chem. (2001) 176:2221-2227.
147. UCKUN FM, NACHMAN JB, SATHER HN et al.: Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk. Lymphoma (1999) 33:101-106.
148. SEIBEL NL, SATHER H, STEINHERZ PG et al.: Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL - Children's Cancer Group 1961. Blood (2000) 96(Suppl. 1):3115a.
149. SZATROWSKI TP, DODGE RK, REYNOLDS C et al.: Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine. Cancer (2003) 97:1471-1480.
150. DINNDORF P, KRAILO M, LIU-MARES W et al.: Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J. Immunother. (2001) 24:511-516.
151. HERRERA L, YARBROUGH S, GHETIE V et al.: Treatment of SCID/human B cell precursor ALL with anti-CD 19 and anti-CD22 immunotoxins. Leukemia (2003) 17:334-338.
152. HARATA M, SODA Y, TANI K et al.: CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood (2004) 104:1442-1449.
153. JANDULA BM, NOMDEDEU J, MARIN P et al.: Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplant. (2001) 27:225-227.
154. LEW G, GU L, ZHOU M et al.: BL22, an anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells from pediatric patients. Blood (2002) 100(Suppl. 1):764a.
155. KOLITZ JE, O'MARA V, WILLEMZE R et al.: Treatment of acute lymphoblastic leukemia (ALL) with Cam path-1H: initial observations. Blood 84(Suppl. 1):1191a.
156. FADERL S, KANTARJIAN HM, O'BRIEN S et al.: A broad exploratory trial of Campath-1H in the treatment of acute leukemias. Blood (2000) 96(Suppl. 1):1397a.
157. WELS W, HARWERTH I-M, MUELLER M et al.: Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the ERB-2 receptor. Cancer Res. (1992) 52:6310-6317.
158. MULLER MR, GRUNEBACH F, KAYSER K et al.: Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin. Cancer Res. (2003) 9:3448-3453.
159. HALLBOOK H, SIMONSSON B, BJORKHOLM M et al.: High dose ara-C as upfront therapy for adult patients with acute lymphoblastic leukemia (ALL). Blood (1999) 94(Suppl. 1):297a.
160. DEKKER AW, VAN'T VEER MB, VAN DER HOLT B et al.: Postremission treatment with autologous stem cell transplantation (Auto-SCT) or allogeneic stem cell transplantation (Allo-SCT) in adults with acute lymphoblastic leukemia (ALL). A Phase II clinical trial (HOVON 18 ALL). Blood (2001) 98(Suppl. 1):859a.
161. BASSAN R, POGLIANI E, CASULA P et al.: Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. Hematol. J. (2001) 2:117-126.
162. ZWAAN C, REINHARDT D, JURGENS H et al.: Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia (2003) 17:468-470.